This piece lays out why Alzheimer’s is a crisis for families and the nation, how science has finally given us tools to spot it early, and why Medicare rules are blocking real progress; it also argues for specific policy fixes so millions can get earlier testing and access to treatments that preserve independence and cut costs.
About one in nine Americans aged 65 and up lives with Alzheimer’s, roughly 7.2 million people, and the shockwaves reach far beyond that number. Partners, adult children, siblings and friends shoulder emotional and financial burdens that are rarely counted in official tallies. When you add everyone affected, the true footprint of this disease stretches into the tens of millions.
Alzheimer’s steals memory, identity and autonomy. Caregivers trade careers and spare time for round-the-clock care, and families often watch a loved one fade while still alive. The emotional toll is matched by financial strain as in-home care or assisted living can drain savings and disrupt futures.
Two decades of focused work have moved the needle. A bipartisan study group in 2007 pushed a national strategy and Congress responded with the National Alzheimer’s Project Act in 2011. The 2025 cure target wasn’t met, but the research spawned real, actionable breakthroughs that matter today.
Scientists have linked Alzheimer’s to amyloid protein buildup in the brain and have shown that tau proteins in the blood can flag trouble before symptoms show up. Reliable blood tests now exist to detect those markers, and infusion therapies can lower amyloid levels. These innovations don’t cure everything overnight, but they create a chance to intervene early and change the disease’s trajectory.
Early detection matters because it buys time. Delaying the slide from mild memory trouble to full-blown dementia can keep people living independently and engaged with family and community for years longer. That extra time is priceless, and it also translates into big savings by postponing or avoiding expensive institutional care.
So why aren’t more families getting these tests and treatments? Medicare rules are the main roadblock. Blood tests that identify tau proteins are covered only after someone reports symptoms, not for proactive screening. Infusion treatments often require participation in a Medicare-approved registry, a step many small and rural providers can’t manage.
Those coverage rules push diagnosis later than it should be and leave many Americans unable to access therapies that might slow decline. The result is a system that treats sickness instead of preventing it, which is both cruel to families and foolish with taxpayer dollars. We need policy that rewards early action, not punishes it with red tape.
Concrete steps would make a real difference. Congress should pass the Alzheimer’s Screening and Prevention Act of 2025, the ASAP Act, to require Medicare coverage of tau protein blood tests so people can detect disease before symptoms force a diagnosis. Medicare should also establish a clear coverage pathway for FDA-approved Alzheimer’s therapies, handled the same way as other drug classes.
These are conservative priorities. They protect independence, strengthen families, and save money by avoiding needless institutional care. Fixing Medicare rules to encourage prevention is common sense: it restores local doctors’ ability to treat patients and stops Washington from standing between science and care.
Benjamin Franklin said, “an ounce of prevention is worth a pound of cure.”
If political will lines up with these scientific advances, we can transform how we manage degenerative disease. It won’t be easy, but giving families the tools to find and treat Alzheimer’s earlier is practical, popular and fiscally responsible, and it deserves action now.
